Quantcast
Last updated on April 23, 2014 at 15:59 EDT

Latest Northwest Biotherapeutics Stories

2013-12-16 08:26:26

Significant Differences In Technology, Trials and Company Positioning Described BETHESDA, Md., Dec. 16, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, today responded to inquiries from shareholders and investors about differences between NW Bio's technology, products and clinical trials and those of a Competitor who recently announced the results of a...

2013-12-05 08:30:07

Presentation by CEO Linda Powers To Be Webcast Live BETHESDA, Md., Dec. 5, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that CEO Linda F. Powers will present at the Oppenheimer 24th Annual Healthcare Conference. The Conference will take place on December 10(th) and 11(th) at the Crowne Plaza Hotel in New York City. (Logo:...

2013-11-19 20:21:39

BETHESDA, Md., Nov. 19, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants to purchase common stock are being offered as units. The proposed offering is subject to market and...

2013-11-08 08:25:30

NYU's Dr. Marc Siegel Discusses DCVax And Its Life-Extending Potential As A Cancer Therapy BETHESDA, Md., Nov. 8, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax(®) personalized immune therapies for solid tumor cancers, announced today that their vaccine was featured yesterday in news coverage on both Fox News and Fox Business News. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO) The...

2013-09-24 08:31:21

MD Anderson Cancer Center Orlando Is Now Also Enrolling Patients BETHESDA, Md., Sept. 24, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that the MD Anderson Cancer Center Orlando has become the second site participating in the Phase I/II clinical trial of DCVax-Direct, the Company's next generation dendritic cell product for the potential...

2013-09-17 08:31:52

Rapid Approval Of Three Minor Amendments; BETHESDA, Md., Sept. 17, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax(®) personalized immune therapies for solid tumor cancers, announced today that the German regulatory authority (the Paul Ehrlich Institute, or PEI) has approved the Company's implementation of the three minor amendments required by the PEI's initial decision announced in August, and has...

2013-09-10 08:30:31

Capital Costs And Manufacturing Time Reduced; Potency And Purity Increased BETHESDA, Md., Sept. 10, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that it has been issued another key U.S. patent (#8,518,636) covering a next generation process for manufacturing lower cost human dendritic cells of both a higher quality and higher reliability....

2013-08-09 08:25:29

Three Adjustments To Be Made, Not Affecting Bases For Seeking Product Approval BETHESDA, Md., Aug. 9, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax(®) personalized immune therapies for solid tumor cancers, announced today that it has received a decision from the German regulatory agency (the Paul Ehrlich Institute, or PEI) under which the Company's Phase III clinical trial will be able to proceed in Germany after the...

2013-08-09 08:25:24

BETHESDA, Md., Aug. 9, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on August 8, 2013, it entered into an agreement with institutional investors, including an existing healthcare focused institutional investor and a dedicated healthcare mutual fund for a registered direct placement of $15 million of common stock at the price of $3.35 per...

2013-07-31 08:30:37

Conversion Shares Also Subject To 18-Month Lock-Up Agreement BETHESDA, M.D., July 31, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax(®) personalized immune therapies for solid tumor cancers, announced today an agreement with the contract manufacturer of its vaccine, Cognate BioServices, Inc. (Cognate), to convert the $11.6 million of accounts payable to Cognate into shares of NW Bio common stock at a price...